About
10
Publications
1,034
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
49
Citations
Introduction
1. Blood-to-brain distribution of radiolabeled peptides/proteins in mouse models of Alzheimer’s disease and insulin resistance.
2. Transport and signaling studies in blood-brain barrier cell culture models.
Skills and Expertise
Current institution
Publications
Publications (10)
Background
A strong body of evidence suggests that cerebrovascular pathologies augment the onset and progression of Alzheimer’s disease (AD). One distinctive aspect of this cerebrovascular dysfunction is the degeneration of brain pericytes—often overlooked supporting cells of blood-brain barrier endothelium.
Objective
The current study investigate...
Blood-brain barrier (BBB) dysfunction is prevalent in Alzheimer’s disease and other neurological disorders. Restoring normal BBB function through RNA therapy is a potential avenue for addressing cerebrovascular changes in these disorders that may lead to cognitive decline. Although lipid nanoparticles have been traditionally used as drug carriers f...
Plasma pharmacokinetic (PK) data is required as an input function for graphical analysis of single positron emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/CT (PET/CT) data to evaluate tissue influx rate of radiotracers. Dynamic heart imaging data is often used as a surrogate of plasma PK. However, accum...
Disruptions in glucose uptake and metabolism in the brain are implicated in metabolic disorders and Alzheimer's disease (AD). Toxic soluble amyloid-beta (sAβ) peptides accumulating in the brain and plasma of AD patients were suggested to promote blood-brain barrier (BBB) dysfunction, brain hypometabolism, and cognitive decline. Exposure to sAβ pept...
Plasma pharmacokinetic (PK) data is required as an input function for graphical analysis (e.g., Patlak plot) of single positron emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/CT (PET/CT) data to evaluate tissue influx rate of radiotracers. Dynamic heart imaging data is often used as a surrogate of plasm...
The compositionally distinct lipid rafts present in the plasma membrane regulates the restrictive trafficking and signal transduction in the blood-brain barrier (BBB) endothelium. Several metabolic and neurodegenerative diseases are associated with lipid homeostasis disruption within the BBB endothelium. Here, we hypothesized that the delivery of l...
![Figure 1. Synthesis of NOTA-insulin and [ 68 Ga]Ga-NOTA-insulin.](publication/359964446/figure/fig1/AS:1159303125843968@1653410812707/Synthesis-of-NOTA-insulin-and-68-GaGa-NOTA-insulin_Q320.jpg)
![Figure 10. Representative microPET/CT images of [ 68 Ga]Ga-NOTA-insulin...](publication/359964446/figure/fig3/AS:1159303125827584@1653410812939/Representative-microPET-CT-images-of-68-GaGa-NOTA-insulin-in-A-normal-and-AD-mice_Q320.jpg)
![Uptake (SUV) of [ 68 Ga]Ga-NOTA-Insulin without and with the Insulin...](publication/359964446/figure/tbl1/AS:1159303130030081@1653410813207/Uptake-SUV-of-68-GaGa-NOTA-Insulin-without-and-with-the-Insulin-Receptor-Inhibitor_Q320.jpg)
Aberrant insulin signaling has been considered one of the risk factors for the development of Alzheimer's disease (AD) and has drawn considerable attention from the research community to further study its role in AD pathophysiology. Herein, we describe the development of an insulin-based novel positron emission tomography (PET) probe, [68Ga]Ga-NOTA...
Background
Decreased brain insulin levels exacerbate cognitive decline in AD. Insulin in the brain is derived from systemic circulation via the blood‐brain barrier (BBB). We hypothesize that type II diabetes (T2D) sequelae and Aβ peptide exposure disrupt insulin signaling at the BBB and inhibit insulin delivery to brain. Further, we propose insulin...
